45.41

6.08% -2.94

Edgewise Therapeutics Inc (EWTX)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$48.35

Offen:

$48.09

24-Stunden-Volumen:

1.07M

Relative Volume:

0.76

Marktkapitalisierung:

$4.89B

Einnahmen:

Nettoeinkommen (Verlust:

$-176.01M

KGV:

-27.34

EPS:

-1.661

Netto-Cashflow:

$-148.97M

1W Leistung:

+14.79%

1M Leistung:

+37.94%

6M Leistung:

+82.37%

1J Leistung:

+227.40%

1-Tages-Spanne:

$43.81

$48.13

1-Wochen-Bereich:

$39.27

$48.40

52-Wochen-Spanne:

$12.30

$48.40

Edgewise Therapeutics Inc Stock (EWTX) Company Profile

Firmenname

Edgewise Therapeutics Inc

Sektor

Healthcare (1096)

Branche

Biotechnology (616)

Telefon

720-262-7002

Adresse

1715 38TH ST, BOULDER

Mitarbeiter

154

Twitter

Nächster Verdiensttermin

2026-08-06

Neueste SEC-Einreichungen

EWTX's Discussions on Twitter

Compare EWTX vs VRTX, REGN, ARGX, ALNY, RVMD

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
EWTX Edgewise Therapeutics Inc	45.41	4.89B	0	-176.01M	-148.97M	-1.661
VRTX Vertex Pharmaceuticals Inc	485.39	123.19B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	664.52	69.67B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	877.62	54.58B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	298.76	39.89B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	186.88	39.73B	742.00K	-1.37B	-1.07B	-7.0731

Edgewise Therapeutics Inc Stock (EWTX) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-09-25	Eingeleitet	Goldman	Neutral
2025-07-30	Eingeleitet	Raymond James	Strong Buy
2025-06-30	Eingeleitet	H.C. Wainwright	Buy
2025-04-30	Eingeleitet	Guggenheim	Buy
2025-04-02	Herabstufung	Scotiabank	Sector Outperform → Sector Perform
2025-03-07	Eingeleitet	Scotiabank	Sector Outperform
2025-01-22	Eingeleitet	Stifel	Hold
2024-11-22	Eingeleitet	Evercore ISI	Outperform
2024-03-07	Eingeleitet	Piper Sandler	Overweight
2023-05-01	Eingeleitet	Truist	Buy
2022-08-25	Herabstufung	Goldman	Neutral → Sell
2022-04-13	Eingeleitet	RBC Capital Mkts	Outperform
2022-01-28	Eingeleitet	Goldman	Neutral

Alle ansehen

Edgewise Therapeutics Inc Aktie (EWTX) Neueste Nachrichten

Jul 11, 2026

Is Edgewise Therapeutics (EWTX) on the Cusp of a Breakthrough Year - Kavout | AI

Jul 11, 2026

Jul 10, 2026

Edgewise Therapeutics Stock Rides A 5-Day Winning Streak To A 23% Gain - Trefis

Jul 10, 2026

Jul 09, 2026

Oppenheimer Initiates Edgewise Therapeutics(EWTX.US) With Buy Rating, Announces Target Price $51 - Moomoo

Jul 09, 2026

CYTK Stock Jumped To Over 2-Year Highs On HCM Trial Outcome – So, Why Are Analysts Bullish On Edgewise Therapeutics? - Stocktwits

Jul 09, 2026

Oppenheimer Initiates Edgewise Therapeutics at Outperform - Moomoo

Jul 09, 2026

EWTX Initiated Coverage by Oppenheimer -- Rating Set to Outperfo - GuruFocus

Jul 09, 2026

Edgewise Therapeutics' EDG-7500 Seen Entering 'Catalyst-Dense' Regulatory Period, Oppenheimer Says - Moomoo

Jul 09, 2026

Oppenheimer initiates Edgewise Therapeutics stock with outperform rating - Investing.com

Jul 09, 2026

Jul 08, 2026

Price to book forward of Edgewise Therapeutics, Inc. – NASDAQ:EWTX - TradingView

Jul 08, 2026

Edgewise Therapeutics stock hits all-time high at 43.96 USD - Investing.com UK

Jul 08, 2026

Edgewise Therapeutics stock hits all-time high at 43.96 USD By Investing.com - Investing.com South Africa

Jul 08, 2026

Price to earnings forward of Edgewise Therapeutics, Inc. – NASDAQ:EWTX - TradingView

Jul 08, 2026

Jul 07, 2026

Edgewise Therapeutics Announces Sale of Sevasemten for Up to $2.65 Billion, Strengthening Balance Sheet and Centering Company Focus on Cardiovascular Pipeline - AOL.com

Jul 07, 2026

Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail

Jul 07, 2026

(EWTX) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily

Jul 07, 2026

Jul 06, 2026

Guggenheim Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating, Raises Target Price to $51 - Moomoo

Jul 06, 2026

Guggenheim raises Edgewise Therapeutics stock price target on Servier deal By Investing.com - Investing.com Canada

Jul 06, 2026

Jul 03, 2026

EWTXEdgewise Therapeutics Inc Options - Finviz

Jul 03, 2026

Jul 02, 2026

Edgewise Therapeutics(EWTX.US) Officer Sells US$7.88 Million in Common Stock - Moomoo

Jul 02, 2026

Edgewise Therapeutics chief scientific officer Alan Russell sells $7.88m By Investing.com - Investing.com South Africa

Jul 02, 2026

Edgewise Therapeutics chief scientific officer Alan Russell sells $7.88m - Investing.com

Jul 02, 2026

Form 4 Edgewise Therapeutics Inc For: 2 July By Investing.com - Investing.com Canada

Jul 02, 2026

Edgewise Therapeutics (EWTX) CSO exercises 200K options and sells 200K shares - Stock Titan

Jul 02, 2026

Jul 01, 2026

Form 4 Edgewise Therapeutics Inc For: 1 July By Investing.com - Investing.com India

Jul 01, 2026

Director Jonathan Fox of Edgewise Therapeutics (EWTX) receives 319-share stock grant - Stock Titan

Jul 01, 2026

[144] Edgewise Therapeutics, Inc. SEC Filing - Stock Titan

Jul 01, 2026

Form 144 | Edgewise Therapeutics(EWTX.US) Director Proposes to Sell 8.13 Million in Common Stocks - Moomoo

Jul 01, 2026

Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules - PR Newswire

Jul 01, 2026

Edgewise lures 2 new employees with 16,500 stock options - Stock Titan

Jul 01, 2026

Jun 29, 2026

Is Edgewise Therapeutics, Inc. (EWTX) A Good Stock To Buy Now? - Insider Monkey

Jun 29, 2026

Jun 28, 2026

EWTX Stock Hits Record High – Why Servier Is Shelling Out $2.65B For Edgewise’s Muscular Dystrophy Business - Stocktwits

Jun 28, 2026

Jun 26, 2026